# Development of minocycline as a neuroimmune therapy for alcohol use disorder

> **NIH NIH K01** · UNIVERSITY OF MARYLAND BALTIMORE · 2021 · $31,420

## Abstract

Project Summary/Abstract
 This supplement application is in response to the Notice of Special Interest (NOT-OD-20-054):
Administrative Supplements to Promote Research Continuity and Retention of NIH Mentored Career
Development (K) Award Recipients and Scholars. The PI is in the fourth year of his K01 Mentored Research
Scientist Development Award, and his wife gave birth to their first child on 05/18/2020. The PI and his wife
have alternated being the sole care providers over the past 10+ months since childbirth. The PI was on official
paternity leave until 12/14/20, and his role as sole caregiver until this return date significantly impeded his
manuscript and grant productivity, K01 training experiences, and K01 research study progress; all difficulties
were further compounded due to the COVID-19 pandemic. The PI is requesting 6 months of research assistant
support ($29,092 in direct costs) to support the completion of his delayed K01 research project and to facilitate
his return to full productivity post-childbirth.

## Key facts

- **NIH application ID:** 10378321
- **Project number:** 3K01AA026005-04S1
- **Recipient organization:** UNIVERSITY OF MARYLAND BALTIMORE
- **Principal Investigator:** Daniel Roche
- **Activity code:** K01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $31,420
- **Award type:** 3
- **Project period:** 2021-05-05 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10378321

## Citation

> US National Institutes of Health, RePORTER application 10378321, Development of minocycline as a neuroimmune therapy for alcohol use disorder (3K01AA026005-04S1). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/10378321. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*